ISRCTN77000698已完成2 期
The role of GABAb receptor mechanisms in cough: a double-blind, randomised controlled trial of Lesogaberan in chronic cough patients with positive and negative symptom association probabilities
niversity Hospital South Manchester0 个研究点目标入组 22 人开始时间: 2015年4月30日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 22
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Provision of signed, written and dated informed consent, prior to any study-specific procedures
- •2. Age over 18 years old
- •3. Agreement to comply with contraception restrictions as outlined in the protocol
- •3. BMI of 19-35 kg/m2 (inclusive)
- •4. Normal spirometry
- •5. Chronic dry cough of at least 8 weeks duration
- •6. Normal chest X-ray
- •7. Patients with cough related to nasal disease, reflux and asthma will be included. These conditions will be investigated but they will still be included
排除标准
- •1. History of cardiac disease, clinically significant orthostatic reactions or syncope, renal disease and hepatic disease
- •2. Prolonged QTcF >450 ms or family history of long QT syndrome at baseline (any prolongation of QTcF during the study will be classed as an AE unless >500 or deemed clinically significant by the research physician)
- •3. Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG at enrolment that may interfere with the interpretation of the QTc interval changes. This includes subjects with any of the following:
- •3.1. Clinically significant PR interval prolongation
- •3.2. Intermittent second or third degree AV block
- •3.3. Incomplete, full or intermittent bundle branch block (QRS <11 ms with normal QRS and T-wave morphology is acceptable if there is no evidence of left ventricular hypertrophy)
- •3.4. Abnormal T-wave morphology, particularly in the protocol defined primary lead
- •4. Any clinically significant illness, medical or surgical procedure or trauma within the 4 weeks preceding the first administration of study medication including upper respiratory tract infections
- •5. Any clinically significant abnormalities in clinical chemistry, haematology results as judged by the investigator
- •6. Abnormal screening clinical pathology values or other clinically significant, unexplained biochemical abnormality according to the investigator; in particular, liver function tests (LFTs) should be within normal limits at screening
- •7. Systolic blood pressure below 110 mmHg at screening
- •8. Current smoker or ex-smoker with >20 pack year history, and <6 months abstinence
- •9. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the investigator, or history of hypersensitivity to drugs with a similar chemical structure or class as Lesogaberan
- •10. History of drug addiction and/or alcohol abuse or other circumstances which in the investigators judgement may compromise the subject’s ability to comply with the study requirements
- •11. Pregnancy or breastfeeding
- •12. Treatment with ACE inhibitors will be excluded. Patients taking centrally acting medications e.g. opiates, amitriptyline, gabapentin, pregabalin for the treatment of cough, will be excluded unless they are willing to stop these treatments. Patients can be included if they are willing to stop opiates for 1 week prior to baseline visit through to follow-up visit. Pregabalin, gabapentin, amitriptyline and ACEi will need to be stopped for 4 weeks prior to baseline visit and through to follow-up visit
- •13. Has received another new chemical entity (defined as a compound which has not been approved for marketing) or has participated in any other clinical study that included drug treatment within 3 months of anticipated first administration of therapy in this study
研究者
相似试验
进行中（未招募）
1 期
Double-Blind Randomised Controlled Trial of Lesogaberan in Chronic Cough PatientsThis means patients will take Lesogaberan and a dummy drug (called placebo) in a random order. During the study neither the study doctor or patient will know whether they are taking Lesogaberan or placebo as the tablets will look identical.Chronic coughMedDRA version: 17.1Level: LLTClassification code 10066656Term: Chronic coughSystem Organ Class: 100000004855EUCTR2014-005074-11-GBniversity Hospital South Manchester NHS Foundation Trust22
已完成
不适用
GARMIn: The Role of GABAB Receptor Mechanisms in CoughTopic: RespiratorySubtopic: Respiratory (all Subtopics)Disease: RespiratoryRespiratoryChronic CoughISRCTN82391675niversity Hospital of South Manchester NHS Foundation Trust (UK)15
已完成
不适用
Pharmacological modulation of the urge to cough: the effects of morphine sulphateChronic coughSigns and SymptomsCoughISRCTN13279602niversity Hospital of South Manchester NHS Foundation Trust60
已完成
不适用
nraveling of neural basis of voluntary cough and cough reflexaspiration pneumoniaJPRN-UMIN000044730Hamamatsu university school of medicine Hamamatsu city rehabilitation hospital24
招募中
不适用
The relationship between the cough response to bronchoconstriction induced by the methacholine provocation using the astographmethod and cough reflex sensitivity to inhaled capsaicin in healthy subjectscough variant asthmaJPRN-UMIN000020804Kanazawa University Graduate School of Medicine30